Biomea Fusion Inc. (BMEA)
NASDAQ: BMEA
· Real-Time Price · USD
2.03
-0.07 (-3.33%)
At close: May 01, 2025, 3:59 PM
2.03
0.00%
Pre-market: May 02, 2025, 08:21 AM EDT
Company Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion Inc.
| Country | United States |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Dr. Michael J. M. Hitchcock Ph.D. |
Contact Details
Address: 900 Middlefield Road Redwood City, California United States | |
| Website | https://biomeafusion.com |
Stock Details
| Ticker Symbol | BMEA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840439 |
| CUSIP Number | 09077A106 |
| ISIN Number | US09077A1060 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael J. M. Hitchcock Ph.D. | Interim Chief Executive Officer & Director |
| Ramses M. Erdtmann | Co-Founder, President, Chief Operating Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEF 14A | Filing |
| Apr 18, 2025 | PRE 14A | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 4 | Filing |
| Mar 27, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 15, 2025 | 8-K | Current Report |